As retirees navigate a challenging macroeconomic climate, the 2026 Social Security cost-of-living adjustment (COLA) of 2.8% has left many searching for alternative income streams. With the 10-year Treasury yielding 4.55% and the national average 12-month CD paying a restrictive 1.65%, building a robust dividend portfolio is a vital strategy. The following five blue-chip dividend payers offer reliable yields backed by strong balance sheets, presenting a viable paycheck replacement strategy.
1. Realty Income (NYSE: O)
Known as the monthly dividend company, Realty Income yields 5.11%. The REIT pays a monthly dividend of $0.271 per share, representing an annualized forward payout of $3.252. In Q1 2026, Realty Income reported an adjusted funds from operations (AFFO) of $1.13 per share, a 6.6% increase year-over-year. Management has raised its FY 2026 AFFO guidance to a range of $4.41 to $4.44 per share, leaving a comfortable margin above its annualized dividend. The real estate investment trust maintains a portfolio occupancy of 98.9% with a rent recapture rate of 103.4%. Its net debt to annualized pro forma adjusted EBITDAre stands at 5.2x. Realty Income boasts a track record of 670 consecutive monthly dividends and 114 consecutive quarterly increases. While the rising interest rate environment poses a challenge—reflected in Q1 2026 impairment provisions of $129.3 million—management is raising its 2026 investment target to $9.5 billion from $8.0 billion. Shares climbed 19.69% year-to-date through July 16.
2. Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson represents the gold standard for defensive investing, holding a rare AAA credit rating. The company pays a quarterly dividend of $1.34 ($5.36 annualized forward), marking 64 consecutive years of distribution growth. JNJ reported Q1 2026 adjusted EPS of $2.70, supporting full-year guidance of $11.45 to $11.65. Free cash flow for FY 2025 reached $19.7 billion. Innovative medicine revenue remains strong, hitting $24.06 billion in Q1 (up 9.9% YoY), led by oncology growth from DARZALEX (up 22.5%), TREMFYA (up 68.3%), and CARVYKTI (up 62.1%). Despite STELARA biosimilar headwinds dragging segment performance by 920 basis points, JNJ’s stock grew 22.13% YTD and 55.49% over the past year.
3. AbbVie (NYSE: ABBV)
AbbVie has continued its stellar payout history since spinning off from Abbott in 2013, yielding 2.76% with a quarterly dividend of $1.73 ($6.92 annualized). Q1 2026 adjusted diluted EPS of $2.65 supported an upward revision for FY 2026 adjusted EPS guidance to a range of $14.08 to $14.28. AbbVie has successfully mitigated the biosimilar erosion of Humira through its next-generation immunology blockbusters Skyrizi (Q1 sales up 30.9% to $4.48 billion) and Rinvoq (up 23.3% to $2.12 billion), alongside a 26.0% rise in neuroscience revenue. AbbVie’s stock has surged 160.34% over the last five years, despite a Q1 EPS headwind of $744 million in IPR&D charges and a 24.7% drop in Imbruvica sales.
4. Verizon Communications (NYSE: VZ)
Verizon serves as the high-yield anchor of defensive portfolios, yielding 6.46% with a quarterly payout of $0.7075 ($2.83 annualized). VZ holds a 19-year dividend growth streak. Q1 2026 adjusted EPS reached $1.28, up 7.6% YoY. For FY 2026, management projects adjusted EPS of $4.95 to $4.99 and free cash flow exceeding $21.5 billion, up from $20.1 billion in FY 2025. Verizon closed its Frontier acquisition on January 20, 2026, boosting its total fiber broadband customer base to 10.8 million subscribers (up 41.9% YoY). The transaction leaves Verizon with $172.5 billion in total debt, pushing interest expenses up 18.9% YoY. Shares are up 13.15% YTD.
5. Altria Group (NYSE: MO)
Altria Group yields 5.96%, paying a quarterly dividend of $1.06 ($4.24 annualized). Altria has increased its dividend 60 times in the last 56 years. In Q1 2026, adjusted diluted EPS grew 7.3% YoY to $1.32. Management reaffirmed its full-year adjusted EPS target of $5.56 to $5.72. The company returned $1.8 billion in dividends during Q1 and repurchased 4.5 million shares under a $2 billion buyback program at an average price of $62.33. Its smokeable products segment recorded a 6.3% OCI increase to $2.68 billion with a 65.1% profit margin. Despite domestic smokeable volumes falling 5% and Marlboro losing 1.4 share points to land at 39.7%, Altria’s shares gained 30.72% YTD.
Frequently Asked Questions
Why is a 2.8% Social Security COLA insufficient for retirees?
A 2.8% cost-of-living adjustment often falls behind actual inflation rates for everyday goods, healthcare, and insurance premiums, making supplementary dividend income essential for maintaining purchasing power.
What is AFFO and why is it important for REIT analysis?
Adjusted Funds From Operations (AFFO) measures a REIT’s recurring cash flow by subtracting capital expenditures from funds from operations (FFO). It is the most accurate metric to gauge a REIT’s ability to cover and grow its dividend.
How do biosimilars affect companies like JNJ and AbbVie?
Biosimilars are generic alternatives to biologic drugs. When blockbusters like STELARA or Humira face biosimilar competition, the patent owners lose market share, requiring them to transition revenue growth to newer drugs like Skyrizi or CARVYKTI to protect cash flows.
